Novel Medication as a Potential Smoking Cessation Aid

• Status: Completed
• Trial end date: 2017-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to provide preliminary information assessing if levomilnacipran may be effective at increasing smoking cessation rates.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Minnesota; University of Minnesota - Clinical and Translational Science Institute
• Treatments: Levomilnacipran; Milnacipran

Criteria

Inclusion Criteria:

• Be between 25 years old and 55 years old

• Smoke a minimum number of cigarettes per day

• Indicate motivation to quit smoking

Exclusion Criteria:

• Current or history of medical or psychiatric conditions that could interfere with measures being studied or that could be affected by the study medication

• Use of medication that could interfere with measures to be studied or that could be expected to interact with levomilnacipran

• Are pregnant or breast feeding

The investigators will evaluate if there are other reasons why someone may not be eligible to participate